📊 LLY Key Takeaways
Is ELI LILLY & Co (LLY) a Good Investment?
Eli Lilly demonstrates exceptional fundamental strength with 94.9% net income growth and 37.4% net margin, coupled with robust $4.0B free cash flow generation. The 49.3x interest coverage ratio provides substantial financial flexibility to manage $39.4B debt while investing in growth.
Eli Lilly’s fundamentals are exceptionally strong, with 44.7% revenue growth, 94.9% net income growth, and very high operating and net margins, indicating that recent growth is translating efficiently into profits. Cash generation is robust, with $15.46B of free cash flow and excellent interest coverage, supporting reinvestment and financial flexibility. The main constraint on an even more aggressive rating is elevated leverage and the need to prove that current growth can remain durable rather than peak-driven.
ELI LILLY & Co Key Strengths (LLY)
- Exceptional profitability with 44.7% operating margin and 37.4% net margin, among the best in pharmaceutical industry
- Accelerating earnings growth of 94.9% YoY combined with 44.7% revenue growth indicates strong operational leverage
- Outstanding free cash flow generation of $4.0B with 20.1% FCF margin, providing ample resources for R&D, acquisitions, and debt service
- Fortress-like interest coverage of 49.3x demonstrates ability to easily service debt despite D/E of 1.26x
- Strong liquidity position with 1.50x current ratio and $5.3B cash reserves providing financial flexibility
- Exceptional top-line and bottom-line growth with revenue up 44.7% and net income up 94.9% YoY
- Very strong profitability profile with 39.5% operating margin, 31.7% net margin, and 77.8% ROE
- High-quality cash generation with $16.81B operating cash flow, $15.46B free cash flow, and 143.3x interest coverage
LLY Stock Risks: ELI LILLY & Co Investment Risks
- Significant debt load of $39.4B creates refinancing risk if borrowing costs rise materially in higher rate environment
- Extraordinarily rapid net income growth of 94.9% may not be sustainable long-term and could reflect favorable product mix, one-time items, or cyclical factors
- Heavy dependence on pharmaceutical pipeline execution; any regulatory rejections or competitive pressures could substantially impact future revenue growth trajectories
- Debt/equity of 1.54x and $40.87B of long-term debt increase balance-sheet leverage risk
- Pharmaceutical earnings can be vulnerable to product concentration, patent cliffs, and regulatory setbacks
- Rapid recent profit expansion may normalize if growth drivers slow or margins compress
Key Metrics to Watch
- Revenue and earnings growth rates over next 2-3 quarters to confirm sustainability of 44-95% growth
- Free cash flow consistency and debt reduction trajectory to assess deleveraging progress
- Operating margin stability as company scales to confirm profitability improvements are structural, not temporary
- Revenue growth and net margin sustainability
- Free cash flow generation relative to debt levels
ELI LILLY & Co (LLY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 20.1% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
LLY Profit Margin, ROE & Profitability Analysis
LLY vs Healthcare Sector: How ELI LILLY & Co Compares
How ELI LILLY & Co compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ELI LILLY & Co Stock Overvalued? LLY Valuation Analysis 2026
Based on fundamental analysis, ELI LILLY & Co has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ELI LILLY & Co Balance Sheet: LLY Debt, Cash & Liquidity
LLY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: ELI LILLY & Co's revenue has grown significantly by 130% over the 5-year period, indicating strong business expansion. The most recent EPS of $5.80 reflects profitable operations.
LLY Revenue Growth, EPS Growth & YoY Performance
LLY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $12.7B | $2.8B | $3.06 |
| Q3 2025 | $11.4B | $970.3M | $1.07 |
| Q2 2025 | $11.3B | $3.0B | $3.28 |
| Q1 2025 | $8.8B | $2.2B | $2.48 |
| Q3 2024 | $9.5B | -$57.4M | $-0.06 |
| Q2 2024 | $8.3B | $1.8B | $1.95 |
| Q1 2024 | $7.0B | $1.3B | $1.49 |
| Q3 2023 | $6.9B | -$57.4M | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ELI LILLY & Co Dividends, Buybacks & Capital Allocation
LLY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for ELI LILLY & Co (CIK: 0000059478)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LLY
What is the AI rating for LLY?
ELI LILLY & Co (LLY) has a Combined AI Grade of A from Claude (A+) and ChatGPT (A) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LLY's key strengths?
Claude: Exceptional profitability with 44.7% operating margin and 37.4% net margin, among the best in pharmaceutical industry. Accelerating earnings growth of 94.9% YoY combined with 44.7% revenue growth indicates strong operational leverage. ChatGPT: Exceptional top-line and bottom-line growth with revenue up 44.7% and net income up 94.9% YoY. Very strong profitability profile with 39.5% operating margin, 31.7% net margin, and 77.8% ROE.
What are the risks of investing in LLY?
Claude: Significant debt load of $39.4B creates refinancing risk if borrowing costs rise materially in higher rate environment. Extraordinarily rapid net income growth of 94.9% may not be sustainable long-term and could reflect favorable product mix, one-time items, or cyclical factors. ChatGPT: Debt/equity of 1.54x and $40.87B of long-term debt increase balance-sheet leverage risk. Pharmaceutical earnings can be vulnerable to product concentration, patent cliffs, and regulatory setbacks.
What is LLY's revenue and growth?
ELI LILLY & Co reported revenue of $19.8B.
Does LLY pay dividends?
ELI LILLY & Co pays dividends, with $1,548.0M distributed to shareholders in the trailing twelve months.
Where can I find LLY SEC filings?
Official SEC filings for ELI LILLY & Co (CIK: 0000059478) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LLY's EPS?
ELI LILLY & Co has a diluted EPS of $8.26.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is LLY's fundamental grade?
Based on our AI fundamental analysis in June 2026, ELI LILLY & Co has a A grade with 86% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is LLY stock overvalued or undervalued?
Valuation metrics for LLY: ROE of 23.7% (sector avg: 15%), net margin of 37.4% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
What is LLY's AI grade for 2026?
Our dual AI analysis gives ELI LILLY & Co a combined A grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is LLY's free cash flow?
ELI LILLY & Co's operating cash flow is $5.3B, with capital expenditures of $1.4B. FCF margin is 20.1%.
How does LLY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 37.4% (avg: 12%), ROE 23.7% (avg: 15%), current ratio 1.50 (avg: 2).